1.41

15.57% 0.19

Pre-market: 1.45 0.04 +2.84%

NanoViricides Inc (NNVC)

Overview News Price History Option Chain Discussions Forecast Stock Split

NanoViricides Inc stock is traded at $1.41, with a volume of 634.42K. It is up +15.57% in the last 24 hours and down -4.73% over the past month. NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Previous Close:

$1.22

Open:

$1.28

24h Volume:

634.42K

Relative Volume:

0.75

Market Cap:

$32.41M

Revenue:

Net Income/Loss:

$-8.09M

P/E Ratio:

-3.2384

EPS:

-0.4354

Net Cash Flow:

$-7.37M

1W Performance:

-1.40%

1M Performance:

-4.73%

6M Performance:

+14.63%

1Y Performance:

-6.62%

1-Day Range:

$1.28

$1.4399

1-Week Range:

$1.22

$1.49

52-Week Range:

$0.85

$2.2299

NanoViricides Inc Stock (NNVC) Company Profile

Name

NanoViricides Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

203-937-6137

Address

1 Controls Drive, Shelton, CT

Employee

Twitter

@nnvcnyse

Next Earnings Date

2026-05-21

Latest SEC Filings

NNVC's Discussions on Twitter

Compare NNVC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NNVC NanoViricides Inc	1.41	32.41M	0	-8.09M	-7.37M	-0.4354
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-25	Initiated	Alliance Global Partners	Buy
Feb-11-15	Initiated	Midtown Partners	Strong Buy

NanoViricides Inc Stock (NNVC) Latest News

Jun 15, 2026

NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for Oral Antiviral NV-387 - citybuzz -

Jun 15, 2026

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire

Jun 15, 2026

Jun 11, 2026

NNVC Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentEarnings Expansion Phase - newsline.com

Jun 11, 2026

Jun 08, 2026

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatmentwith Superior Oral Administration and Escape Resistance Features Over Antibodies - ACCESS Newswire

Jun 08, 2026

NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan

Jun 08, 2026

Jun 05, 2026

NanoViricides Files for $50 Million Mixed Shelf Offering - Moomoo

Jun 05, 2026

NNVC stock up 17% today: What’s driving the rally? - MSN

Jun 05, 2026

Jun 04, 2026

NanoViricides (NNVC) Edges Lower Within Narrow Trading RangePre-Earnings Momentum - newsline.com

Jun 04, 2026

Jun 01, 2026

NanoViricides (NNVC) Slides 3.6% as Selling Pressure IntensifiesInstitutional Buy Signals - The Legal Advocate

Jun 01, 2026

May 30, 2026

NanoViricides (NNVC) Retreats 4.3%, Nears Critical Support at $1.69AAII Bullish - thelegaladvocate.com

May 30, 2026

Ebola Global Health Emergency Needs a Broad-Spectrum DrugNV-387 is a Strong Potential Candidate, Says NanoViricides - ACCESS Newswire

May 30, 2026

NNVC Q1 2026 Earnings: EPS Surpasses Expectations Amid Ongoing Development EffortsEPS Surprise History - newsline.com

May 30, 2026

May 29, 2026

NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill

May 29, 2026

May 28, 2026

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire

May 28, 2026

May 27, 2026

Nanoviricides(NNVC) Stock Options Chain | Quotes & News - Moomoo

May 27, 2026

NanoViricides (NNVC) Surges 15.9% as Speculative Buying Drives Shares Above $1.75MA Cross Alert - The Legal Advocate

May 27, 2026

NanoViricides (NNVC) Surges 13.6% as Stock Approaches Key ResistanceSwing Trade Setups - The Legal Advocate

May 27, 2026

NNVC Stock Gains Attention As NV-387 Targets Ebola And Measles - StocksToTrade

May 27, 2026

NNVC Stock Draws Traders As NV-387 Targets Ebola, Measles - timothysykes.com

May 27, 2026

May 26, 2026

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides - ACCESS Newswire

May 26, 2026

Contact | Statesman-Examiner - FinancialContent

May 26, 2026

Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan

May 26, 2026

May 25, 2026